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Novelty and Impact 
Patients with invasive breast cancer are at long-term increased risk of developing depression, anxiety 
and stress-related disorders. Risk of mental disorders was highest shortly after diagnosis, especially 
among young patients presenting with aggressive tumor characteristics and undergoing chemotherapy. 
2 
Patients with in-situ breast cancer only experienced a short-term increased risk of stress-related 
disorders. The observed time-dependent risk patterns shed light on the need of timely interventions for 
specific subgroups of invasive breast cancer patients. 
3 
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Despite concerns about the mental health of breast cancer patients, little is known regarding the temporal 
risk pattern and risk factors of common mental disorders among these patients. We estimated 
standardized incidence ratios (SIRs) of depression, anxiety and stress-related disorders in a Swedish 
nationwide cohort of 40,849 women with invasive and 4,402 women with in-situ breast cancer (2001-
2010, median follow-up = 4.5 years). The impact of patient, tumor and treatment characteristics was 
analyzed using flexible parametric survival models in a regional cohort of 7,940 invasive breast cancer 
patients (2001-2013, median follow-up = 7.5 years). Women with invasive breast cancer showed 
increased rates of depression, anxiety and stress-related disorders [overall SIR (95% CI) = 1.57 (1.46-
1.69), 1.55 (1.43-1.68) and 1.77 (1.60-1.95), respectively]. SIRs were highest shortly after diagnosis, but 
remained increased up to 5 years. Younger age at diagnosis, comorbidity, higher-grade disease, lymph 
node involvement and chemotherapy were independently associated with the risk of depression and 
anxiety in invasive cancer patients, with chemotherapy and higher-grade disease conferring short-term 
risk only, while comorbidities were mainly associated with late-onset events. No clinical risk factors were 
identified for stress-related disorders except for a greater risk associated with younger age. Patients with 
in-situ cancer only showed an increased incidence of stress-related disorders during the first six months 
after diagnosis [SIR (95% CI) = 2.76 (1.31-5.79)]. The time-dependent risk profile of invasive cancer 
patients may guide health care professionals for timely and targeted psycho-oncologic interventions. 
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Breast cancer is increasingly prevalent nowadays, and mental disorders caused by the existential 
threat of the disease and its therapeutic side effects are common in breast cancer 1, 2. Consequently, more 
breast cancer patients than before are suffering from mental disorders 3, including mainly depression, 
anxiety, and stress-related disorders 4. The burden of these disorders is substantial, as patients with a 
comorbid mental disorder are not only affected in their psychological well-being, but also experience 
problems in work performance 5, treatment adherence 6, 7, and overall quality of life 8 .    
Despite the considerable impact on long-term health, little is known about the time-dependent risk 
pattern of depression, anxiety and stress-related disorders in breast cancer patients. Previous studies have 
mainly focused on depression or anxiety, and were limited by cross-sectional design or short-term follow-
up 3, 9-14. As a result, risks by time since diagnosis have rarely been described. Moreover, few studies have 
addressed the mental health situation of carcinoma in-situ patients 15-17. A lower incidence of depression 
has been reported among patients with in-situ compared to invasive breast cancer 18. However, whether or 
not these patients experience similar risks of depression and other mental disorders compared to the 
general female population is unknown.  
Available evidence regarding the impact of patient, tumor and treatment characteristics is also not 
entirely consistent. Most large-scale studies have reported a strong influence of non-tumor-related factors 
(e.g. younger age at diagnosis and comorbidity) on the risk of depression and anxiety 3, 9, 10, 19, but the 
impact of chemotherapy and tumor-related characteristics is less conclusive 19-21. Part of this 
inconsistency might be due to the presence of time-dependent effects, which are particularly relevant for 
tumor and treatment-related factors as their effect may diminish once the diagnosis is set or therapy is 
completed. Since the efficacy of preventive measures is dependent on early and timely interventions, 
time-dependent analyses may help to identify subgroups of patients at greatest risk by time since 
diagnosis. 
In the present study, we aimed to assess the risks of depression, anxiety and stress-related disorders 
in a large nationwide cohort including patients with invasive and in-situ breast cancers. We further aimed 
to identify high-risk patient groups by doing additional analysis in a regional cohort of invasive breast 
cancer patients with detailed information on patient, tumor and treatment characteristics, and considering 




We performed a Swedish register-based study including: 1) a nationwide cohort of invasive and in-
situ breast cancer patients; and 2) a regional cohort including invasive breast cancer patients in the 
Stockholm-Gotland area. (Figure 1) 
The nationwide cohort was defined based on the Swedish Cancer Register and included all women 
diagnosed with primary invasive or in-situ breast cancer (N=50,652) at the age of 20-80 years between 
2001 and 2009. In Sweden, diagnoses of invasive and in-situ breast cancers are reported by a pathologist 
according to international rules and the register is considered to have almost 100% completeness 22, 23. To 
estimate the relative risks of depression, anxiety and stress-related disorders, the nationwide cohort was 
compared to the general female population identified from the Swedish national census conducted in 
1990 (including 3,545,230 women).  
The regional cohort included 9,038 women diagnosed with primary invasive breast cancer (at the 
age of 20-80 years) between 2001 and 2008 as identified through the Stockholm-Gotland Breast Cancer 
Register. This quality register on breast cancer has about 99% completeness and provides detailed 
information on tumor and treatment characteristics and routine follow-up on locoregional recurrences and 
distant metastases 24.  
Follow-up of the nationwide cohort started from the date of breast cancer diagnosis, and ended on 
the date of the first mental health outcome, death, emigration, a new cancer diagnosis or end of follow-up 
(December 31st, 2010),whichever came first. Information on death and emigration was obtained through 
cross-linking the cohort to the Swedish Causes of Death Register and the Swedish Migration Register, 
using the unique personal identification numbers. Follow-up of the regional cohort was conducted in the 
same manner as the nationwide cohort, except for an extension of follow-up until December 31st, 2013. 
Median follow-ups of the nationwide and regional cohorts were 4.5 years (max 10 years) and 7.5 years 
(max 13 years), respectively (Table 1). 
The study was approved by the Regional Ethical Review Board in Stockholm, Sweden. 
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Mental health outcomes  
All mental health outcomes were identified through the Swedish Patient Register, which has 
nationwide coverage for inpatient hospitalizations in Sweden since 1987. Since 2001, Swedish counties 
are also obliged to report hospital-based outpatient physician visits. In Sweden, individuals visiting  
hospital-based psychiatric clinics following a primary care’s doctor referral are interviewed by 
psychiatrists, who make  diagnostic decisions according to the World Health Organization guidelines on 
mental disorders 25. All diagnoses were coded according to the Swedish version of the 10th revision of the 
International Classification of Diseases (ICD-10): depression (F32-F33), anxiety (F40-F41) and stress-
related disorders (F43) (eTable 1). For the present analysis, only primary diagnoses based on either an 
inpatient or outpatient hospital visit were considered. Since we aimed to study new-onset events, patients 
who had been diagnosed with a mental disorder [ICD-10 (1997-) : F0-F4; ICD-9 (1987-1996) : 290-300, 
303-306, and 308-311; and  ICD-8 (1969-1986) : 290-300, 303-305, 307, and 309] prior to the breast 
cancer diagnosis were excluded from the cohort, leaving 40,849 patients with invasive and 4,402 patients 
with in-situ cancer in the nationwide cohort, and 7,940 patients with invasive cancer in the regional 
cohort. (Figure 1) 
To complement the definition of mental health outcomes based on hospital diagnoses, we also 
assessed the incidence of psychiatric medication use, extracted from the Swedish Prescribed Drug 
Register. Psychiatric medications were defined according to the Anatomical Therapeutic Chemical (ATC) 
Classification System: antidepressant (N06A), anxiolytics (N05B), hypnotics and sedatives (N05C). 
Since prescription data are only available from July 2005 onward, we only included breast cancer patients 
diagnosed between July 1st 2006 and December 31st 2009, and excluded patients who had a prescription 
of antidepressants, anxiolytics, hypnotics and/or sedatives in the year prior to the breast cancer diagnosis, 
leaving 19167 patients for this analysis. The same exclusion criteria were applied to the general 
population cohort. Follow-up time started from July 1st 2006 and ended at the date of prescription, death, 
emigration, a new primary cancer diagnosis, or December 31st 2010, whichever came first.   
Patient, tumor and treatment characteristics 
We extracted the following patient, tumor and treatment characteristics from the Stockholm-
Gotland Breast Cancer Register for the regional cohort of invasive breast cancer patients: age at diagnosis, 
tumor size, histological grade, estrogen receptor (ER) status, axillary lymph node involvement, distant 
metastasis, chemotherapy, endocrine therapy, radiotherapy, and surgery. Information on comorbidities 
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prior to diagnosis was obtained from the Swedish Inpatient Register and summarized according to the 
Charlson Comorbidity Index (CCI) score 26.   
Statistical analyses 
We first compared the risk of depression, anxiety and stress-related disorders in invasive and in-situ 
breast cancer patients with that observed in the general population using standardized incidence ratios 
(SIRs; the ratio of observed number of events to expected number of events), overall and stratified by age 
and time since diagnosis. The expected number of events was calculated by multiplying the number of 
person-years observed in age (5-year categories), calendar period (1-year categories), and region of 
residence (North, Stockholm-Gotland, South, Southeast, Uppsala-Örebro, West) specific strata of the 
breast cancer cohorts by the incidence rates of each outcome in the corresponding strata of the general 
female population. Calculation of the confidence intervals (CIs) was based on Poisson distribution and 
potential linear trends of SIRs by age group were examined using Chi-Square tests. We used Kaplan-
Meier curves to assess the cumulative incidences of all three mental health outcomes and compared these 
to the cumulative incidences observed in age-matched individuals from the general population. 
In the regional cohort, we further analyzed the risk of depression, anxiety and stress-related 
disorders by patient, tumor and treatment characteristics. Flexible parametric survival models 27 were 
used to estimate hazard ratios (HRs) with 95% CIs and the proportional hazards assumption was tested 
using likelihood ratio tests of time by covariate interactions. The flexible parametric model is similar to 
the Cox proportional hazards model in that it provides a HR and additionally allows the effect of 
exposure variables to vary over time. In all models, time since diagnosis was the underlying time scale 
and a restricted cubic spline, with four internal and two boundary knots (five degrees of freedom) placed 
at quintiles of the event times, was used for the baseline hazard. In case of non-proportionality, time-
dependent effects were modelled by adding interaction terms with time using a second spline with three 
degrees of freedom and HRs were reported at different time points after diagnosis. 
We constructed three models to analyze the impact of patient, tumor and treatment related factors: 1) 
models adjusting for age and calendar period of diagnosis. 2) grouped models including respectively all 
patient, all tumor or all treatment characteristics with additional adjustment for age and calendar period; 3) 
multivariable models including all variables. Missing indicators were included for the analysis of tumor 
and treatment characteristics in all models.  We also conducted two extra analyses to evaluate the impact 
of disease recurrence and newly developed comorbidities on the association with patient, tumor and 
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treatment characteristics. For this analysis, person-time was additionally censored at recurrent events 
(defined as distant metastasis or locoregional recurrence) or diagnosis of new comorbid disease during 
follow-up. 
Statistical analyses were performed using Stata software (version 13.0; Stata Corporation, College 
Station, TX). 
Results 
Risk of depression, anxiety and stress-related disorders in breast cancer patients compared to the 
general female population 
Patients with invasive breast cancer were at increased risk of developing mental disorders compared 
to the general female population (Table 2), with the overall SIRs being of similar magnitude for 
depression, anxiety and stress-related disorders [SIR (95% CI) = 1.57 (1.46-1.69), 1.55 (1.43-1.68) and 
1.77 (1.60-1.95), respectively]. Risk of mental disorders was highest during the first year after diagnosis, 
with the SIR for stress-related disorders being most pronounced (SIR0-6month= 4.22, 95% CI = 3.44-
5.19).The SIRs for all three mental disorders remained elevated up to five years. No overall increased risk 
of mental disorders was found among patients with in-situ breast cancer, except for an increased risk of 
stress-related disorders shortly after diagnosis (SIR 0-6 months = 2.76, 95% CI = 1.31-5.79). 
 In invasive cancer patients, the risk of depression and anxiety was highest among those diagnosed 
at younger age (P for trend = 0.03 and 0.02 respectively), while no interaction with age was found for 
stress-related disorders.  SIRs for mental disorders did not vary by age in patients with in-situ breast 
cancer.  
Patients with invasive cancer were more likely to receive psychiatric medication prescriptions, with 
SIRs for all medications being long-term increased (up to 4.5 years), but of highest magnitude during the 
first months after diagnosis.  In-situ breast cancer patients were also more likely to use psychiatric 
medications, especially shortly after diagnosis with only the SIR for antidepressants being increased up to 
2 years (eTable 2). In invasive cancer patients, a similar age trend for psychiatric medication use was 
observed as for the anxiety and depression diagnoses, with SIRs for all types of medication being highest 
in those diagnosed at younger age. As for the clinical diagnoses, no age interaction was found for 
psychiatric medication use in patients with in-situ cancers.   
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Figure 2 shows the cumulative incidences of mental disorders by time since diagnosis. The 5-year 
cumulative incidences of depression, anxiety and stress-related disorders in invasive cancer patients were 
2.1%, 1.5% and 1.1% respectively. The corresponding cumulative incidences were respectively 1.4%, 
1.1% and 0.7% for in-situ cancer patients and 1.2%, 0.9% and 0.6% for the general population. 
Risk of depression, anxiety and stress-related disorders by patient, tumor and treatment 
characteristics in invasive breast cancer patients  
Risk profiles of invasive cancer patients were similar for depression and anxiety in multivariable 
models (Table 3), with younger patients and patients with comorbidities being at higher risk. We also 
observed an increased risk of anxiety in patients with distant metastases, higher-grade tumors and 
chemotherapy treatment, as well as an increased risk of depression in patients with a positive lymph node 
status. In contrast, no clinical risk factors were found for stress-related disorders, except for an increased 
risk with younger age at diagnosis. Overall, associations with histological grade, lymph node status and 
chemotherapy were stronger in grouped models (including only tumor or treatment factors), highlighting 
the close correlation between these variables (eTable 3).  
Tests for proportional hazards showed that the effects of comorbidities, histological grade and 
chemotherapy were not constant over time (Figure 3 and eTable 4). Comorbidities were only associated 
with increased risks of depression and anxiety ~3 years after diagnosis, while the impact of histological 
grade and chemotherapy was mainly limited to the first two years after diagnosis.  
Analyses with additional censoring at recurrent events or newly developed comorbidities returned 
similar effect estimates (eTable 5), indicating that these events had no strong impact on the observed 
associations with patient, tumor and treatment characteristics. 
Discussion 
Key results 
In this large-scale register-based study, we found that patients with invasive breast cancer had a 
60% increased risk of developing depression, anxiety and stress-related disorders within 10 years of 
diagnosis, compared to the general female population. Although mental disorder risk was highest shortly 
after diagnosis, the incidence of all three mental disorders remained increased up to five years. Younger 
age at diagnosis, comorbidities, higher histological grade, positive lymph node status and chemotherapy 
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were all independently associated with the risk of depression and anxiety in invasive cancer patients, with 
histological grade and chemotherapy contributing to short-term risk only, while comorbidities were 
mainly associated with late-onset events. Younger age at diagnosis was the only identifiable risk factor 
for stress-related disorders in invasive breast cancer patients. No overall increased risk of mental 
disorders was found among patients with in-situ breast cancer, except for an increased risk of stress-
related disorders in the first six months after diagnosis. 
Interpretation 
Few studies have evaluated the risk of depression, anxiety and stress-related disorders in breast 
cancer patients as compared to the general population. The risk estimates observed for depression and 
anxiety in invasive breast cancer patients are in agreement with findings from two Danish register-based 
studies 19, 28, supporting the generalizability of risk estimates within Nordic countries. Of note, the 
cumulative incidences in register-based analyses are lower than the incidences observed in studies using 
clinical interviews 4, 29, 30, which may indicate that our absolute risk estimates represent an 
underestimation, but capture the most severe and clinically relevant cases. The higher incidence of 
psychiatric medication prescriptions than hospital visits also support this argument.  
The excess risk of mental disorders shortly after diagnosis can be explained by direct psychological 
reactions to the actual diagnosis 31. In addition, we found a long-term increased risk of depression, 
anxiety and stress-related disorders, potentially due to side effects from extensive medical treatment, or 
medical sequelae of breast cancer (such as lymphedema, numbness in hands and chest) which may trigger 
the re-experience of a traumatic event 32, 33.  
Patients diagnosed with in-situ breast cancer did not show an increased risk of mental disorders, 
except for a nearly three-fold increased risk of stress-related disorders in the first six months after 
diagnosis, as well as a short-term increased risk of psychiatric medication use. One explanation is that in-
situ breast cancer is generally conceived less of a life threatening disease. Moreover, patients with in-situ 
breast cancer do not experience strong side effects of chemo/endocrine therapy, as they usually undergo 
surgery and/or radiotherapy only. 
A large number of studies have assessed the risk of mental disorders by patient, tumor and 
treatment characteristics 3, 9, 10, 19-21, and younger age at diagnosis has consistently been associated with an 
increased risk of depression and anxiety 9, 19, 28, 34, 35. The lower mean age at diagnosis of depression and 
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anxiety than the mean age of breast cancer diagnosis (Table 1) also supports this notion. The impact of 
age is usually attributed to more aggressive tumor characteristics and treatment in younger patients 36, but 
our study demonstrates that the effect of age is independent of cancer subtype and treatment. Younger age 
at diagnosis was also the only risk factor related to stress-related disorders, which is in agreement with 
previous studies 37, 38, stressing the importance of this factor as indicator of overall mental disease risk 34, 
37, 39. In general, younger patients might experience greater psychological distress from a cancer diagnosis, 
as a diagnosis early in life may have a larger impact on future well-being from a personal, socioeconomic 
and physical perspective. In case of breast cancer, a younger age at diagnosis is more likely to influence 
work ability 5, sexual life 40, motherhood 41 and fertility 42 compared to a diagnosis later in life.  
We also found an increased risk of depression and anxiety in patients with higher histological 
grade, lymph node positive disease and in patients treated with chemotherapy, as suggested by previous 
observations 19, 20, 34, 37, 43. Patients might interpret higher histological grades and lymph node spread as a 
more severe diagnosis, and the effect of such mental reaction to diagnosis is expected to diminish with 
time, as corroborated by the short-term effect of grade in the present study.  An impact of chemotherapy 
on mental health is biologically plausible. Release of pro-inflammatory cytokines during chemotherapy-
induced cell damage may influence mood disorder pathophysiology 44-46. Side effects of chemotherapy 
such as alopecia, nausea and vomiting may further increase the risk of depression and anxiety 47, 48. Still, 
several population-based studies have reported conflicting results regarding the impact of chemotherapy 
on depression and anxiety 3, 19, 21. One explanation for this inconsistency is the time-dependent effect of 
chemotherapy, as the impact of chemotherapy was only detectable in first two years after diagnosis, i.e. 
during and shortly after active treatment. 
 We further identified an independent association of comorbidities with the risk of depression and 
anxiety. Comorbidity is an established risk factor for mental disorders 9, 19. Besides baseline comorbidity, 
cancer treatment may trigger new comorbid events, which could potentially increase the long-term risk of 
mental disorders. However, the consistent results in the extra analysis with additional censoring at these 
events do not support this hypothesis.  Our study further shows that the impact of baseline comorbidities 
becomes more evident with increasing time since diagnosis. Together with the findings of 
tumor/treatment characteristic analyses, these results indicate that the short-term risk of depression and 
anxiety in breast cancer patients is more strongly influenced by cancer-specific factors, while comorbid 
conditions only have an impact in the long run. Thus, the individual risk profile of mental disorders is not 
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constant in breast cancer patients, but changes over time with respect to comorbidities, chemotherapy and 
histological grade. 
Previous studies have shown that early short-term psycho-oncologic interventions (including 
education, coping skills training, psychotherapy and relaxation) are effective in controlling emotional 
distress, anxiety and depression, and that the largest effects are seen in studies which preselect cancer 
patients according to their personal distress levels 49, 50 . Our findings suggest that apart from emotional 
distress, knowledge of baseline clinical parameters may aid in the identification of patients in highest 
need for intervention. For example, young breast cancer patients presenting with aggressive tumor 
characteristics scheduled for chemotherapy may potentially benefit from targeted screening and 
counseling shortly after diagnosis. Simultaneously, the long-term increased risks of mental illness may 
indicate a need for long-term vigilance of specific subgroups based on age and comorbidity, though 
effectiveness data on continuous interventions in long-term survivors are scarce and require further study. 
Strengths and Limitations  
A major strength of our study is the large-scale population-based design and use of Swedish health 
registers, which minimizes selection and information biases. Other strengths include the abundant 
information on tumor and treatment characteristics in the regional breast cancer cohort and the use of 
flexible parametric models for capturing time dependent effects. 
The present study also had limitations. First, we cannot rule out misclassification of the outcomes 
studied. Although recent validation studies have reported good agreement (more than 80%) between the 
Patient Register and medical records review/clinical diagnoses of depression and stress-related disorders 
51, 52, no validation data are available for anxiety. Since the diagnostic work-up for anxiety is not different 
from depression and stress-related disorders (with primary care doctor’s referral and interview by a 
psychiatrist), the validity of this outcome is considered to be of similar quality. We further tried to 
minimize potential misclassification by using main diagnoses only.  Second, breast cancer patients are 
subject to increased medical surveillance than healthy individuals in the general population, especially 
shortly after diagnosis. Hence, the SIRs for mental disorders might be slightly over-estimated, although 
the long-term increased risk of depression and anxiety argues against a pure explanation of surveillance 
bias for the increased risks shortly after cancer diagnosis. Third, associations with tumor and treatment 
characteristics were addressed in the regional cohort only, as pathology and in-hospital treatment data are 
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not included in the nationwide cohort. Since oncological clinical practice does not vary across different 
regions of Sweden 53, 54 , we believe that these results are generalizable to the country as a whole. Also, 
we did not have information on psychosocial variables (such as previous traumatic life events, family 
history of mental disorders, socioeconomic and cohabitation status) in the regional cohort. Likewise, 
more detailed information on molecular subtyping may further facilitate the discrimination of aggressive 
cancers and the associated risk of mental disorders in future studies. Finally, the limited number of events 
among in-situ breast cancer patients may have resulted in reduced statistical power to identify 
associations, mainly in stratified analyses by age and time since diagnosis. Nevertheless, confidence 
intervals were reasonably narrow and results from the more powerful medication analysis were 
confirmatory, all arguing against a long-term increased risk of mental disorders and age-specific effects in 
this group of patients.  
 
Conclusion  
Patients with invasive breast cancer are at long-term increased risk of developing depression, 
anxiety and stress-related disorders, with risks being highest shortly after diagnosis. Younger age at 
diagnosis, comorbidity, higher-grade disease, lymph node involvement and chemotherapy are 
independent predictors of mental disorder risk, with tumor and treatment variables mainly influencing 
short-term risk, while comorbidities are more strongly associated with late-onset events. Patients with in-
situ breast cancer only experience a short-term increased risk of stress-related disorders. The observed 
time-dependent risk profiles shed light on the needs of early interventions for specific subgroups of 
invasive breast cancer patients. 
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Figure 1. Flow chart of study population selection. 
 
Figure 2. Cumulative incidence of depression, anxiety and stress-related disorders in the nationwide 
cohort of invasive and in-situ breast cancer patients and the general female population.  
Kaplan-Meier estimates of the cumulative risk of depression, anxiety and stress-related disorders by time 





Figure 3. Time-dependent effect of comorbidity, histological grade and chemotherapy on depression and 
anxiety in the regional cohort of invasive breast cancer patients. 
Hazard ratios by time since diagnosis are derived from flexible parametric survival models. All hazard 
ratios are multivariable adjusted.
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Table 1. Descriptive characteristics of the nationwide and regional breast cancer cohort. 
 Nationwide cohort  Regional cohort 
 Invasive breast cancer In-situ breast cancer  Invasive Breast cancer 
 (N =  40,849) (N = 4,402)  (N = 7,940) 
Cohort period 2001-2010 2001-2010  2001-2013 
Age at diagnosis (years)     
  Mean (SD) 60.0 (11.1) 58.2 (10.3)  58.5 (11.3) 
  Min – Max 20-80 22-80  23-80 
Duration of follow-up (years)     
  Median (IQR) 4.5 (4.5) 4.7 (4.4)  7.5 (4.6) 
Total no. of person years at risk 194,122 21,482  58,273 
Cases of mental disorders     
    Depression (% of patients) 759 (1.9%) 56 (1.3%)  335 (4.2%) 
    Anxiety (% of patients) 572 (1.4%) 41 (0.9%)  362 (4.6%) 
    Stress-related disorders (% of patients) 384 (0.9%) 26 (0.6%)  147 (1.9%) 
Age at mental disorder diagnosis (years)     
   Mean age at depression (SD) 58.8 (11.5) 58.1 (11.4)  55.9 (11.7) 
   Mean age at anxiety (SD) 58.2 (12.0) 58.4 (12.1)  55.3 (12.6) 
   Mean age at stress-related disorders (SD) 54.7 (10.5) 57.3 (7.0)  53.1 (10.7) 
 
Abbreviations: SD = standard deviation; IQR = interquartile. The nationwide cohort includes women diagnosed with primary invasive or in-situ breast cancer at age 20-80 
years between 2001 and 2009. In this cohort, follow-up is complete until December 31st, 2010. The regional cohort includes women diagnosed with primary invasive breast 




Table2. Standardized incidence ratios of depression, anxiety and stress-related disorders in the nationwide breast cancer cohort 
  Depression   Anxiety  Stress-related disorders 
 No. SIR(95%CI)  No. SIR(95%CI)  No. SIR(95%CI) 
Overall         
Invasive 759 1.57 (1.46-1.69)  572 1.55 (1.43-1.68)  384 1.77 (1.60-1.95) 
In situ 56 1.03 (0.80-1.34)  41 0.99 (0.73-1.34)  26 1.02 (0.70-1.50) 
Age group         
Invasive         
20-44 years 128 1.69 (1.42-2.01)  117 1.84 (1.54-2.21)  84 1.68 (1.36-2.08) 
45-54 years 238 1.70 (1.50-1.93)  165 1.56 (1.34-1.81)  149 1.78 (1.52-2.09) 
55-64 years 208 1.56 (1.36-1.79)  163 1.58 (1.35-1.84)  105 1.89 (1.56-2.28) 
65-80 years 185 1.38 (1.19-1.59)  127 1.31 (1.10-1.56)  46 1.64 (1.23-2.19) 
In-situ         
20-44 years 12 1.48 (0.84-2.61)  8 1.18 (0.59-2.36)  2 0.38 (0.09-1.51) 
45-54 years 16 0.84 (0.51-1.36)  14 0.97 (0.57-1.64)  12 1.06 (0.60-1.87) 
55-64 years 15 1.01 (0.61-1.68)  11 0.95 (0.53-1.72)  9 1.46 (0.76-2.81) 
65-80 years 13 1.07 (0.62-1.85)  8 0.91 (0.45-1.81)  3 1.15 (0.37-3.56) 
Time since diagnosis        
Invasive         
0-0.5 year 86 1.83 (1.48-2.26)  85 2.53 (2.05-3.13)  91 4.22 (3.44-5.19) 
0.5-1 year 117 2.48 (2.07-2.97)  79 2.30 (1.85-2.87)  59 2.73 (2.11-3.52) 
1-2 years 180 2.04 (1.76-2.36)  131 2.00 (1.69-2.38)  70 1.72 (1.36-2.17) 
2-5 years 249 1.29 (1.14-1.46)  172 1.17 (1.01-1.36)  119 1.36 (1.14-1.63) 
5-10  years 127 1.18 (0.99-1.41)  105 1.18 (0.97-1.42)  45 0.98 (0.73-1.32) 
In situ         
       0-0.5 year 4 0.77 (0.29-2.05)  2 0.53 (0.13-2.12)  7 2.76 (1.31-5.79) 
       0.5-1 year 6 1.14 (0.51-2.54)  0 -  2 0.78 (0.20-3.14) 
       1-2 years 9 0.91 (0.47-1.74)  12 1.62 (0.92-2.85)  5 1.04 (0.43-2.51) 
       2-5 years 25 1.15 (0.78-1.70)  18 1.09 (0.68-1.73)  9 0.88 (0.46-1.69) 
       5-10  years 12 1.00 (0.57-1.76)  9 0.90 (0.47-1.74)  3 0.57 (0.18-1.76) 
 
Abbreviations: SIR = standardized incidence ratio; No. refers to the number of observed cases; CI = confidence interval. SIRs for depression, anxiety and stress-related 
disorders in the nationwide breast cancer cohort compared to the entire Swedish female population (age 20-80). The SIR is the number of observed cases divided by the 
number expected, and can be interpreted as measure of relative risk (i.e. a SIR of 1.5 represents a 50% increase in risk). All SIRs are standardized by calendar period (1-year 




Table 3. Hazard ratios of depression, anxiety and stress-related disorders according to patient, tumor and treatment characteristics in the regional cohort of invasive 
breast cancer patients.  
  Depression  Anxiety  Stress related disorders 
 Total 
No. No. 
HR (95%CI)  No. HR (95%CI)  No. HR (95%CI)  Model A Model B  Model A Model B  Model A Model B 
Patients characteristics             
Age at diagnosis 
            
23-44 years 1012 86 REF (1.00) REF (1.00) 
 
114 REF (1.00) REF (1.00) 
 
47 REF (1.00) REF (1.00) 
45-54 years 1913 115 0.69 (0.52-0.92) 0.77 (0.58-1.03) 
 
109 0.50 (0.38-0.65) 0.53 (0.41-0.69) 
 
64 0.71 (0.49-1.03) 0.70 (0.48-1.03) 
55-64 years 2629 80 0.35 (0.26-0.48) 0.40 (0.30-0.55) 
 
86 0.28 (0.21-0.38) 0.32 (0.24-0.43) 
 
26 0.21 (0.13-0.34) 0.20 (0.12-0.33) 
65-80 years 2386 54 0.28 (0.20-0.39) 0.33 (0.23-0.47) 
 
53 0.20 (0.15-0.28) 0.22 (0.16-0.32) 
 
10 0.10 (0.05-0.19) 0.09 (0.04-0.18) 
Comorbidities †     
   
  
   
  
  
No 6797 287 REF (1.00) REF (1.00) 
 
304 REF (1.00) REF (1.00) 
 
128 REF (1.00) REF (1.00) 
Yes  1143 48 1.43 (1.04-1.94) 1.44 (1.05-1.97) 
 
58 1.72 (1.30-2.29) 1.67 (1.25-2.23) 
 
19 1.50 (0.92-2.44) 1.49 (0.91-2.44) 
Tumor characteristics   
            
Size in mm 
            
  <10 1867 71 REF (1.00) REF (1.00) 
 
69 REF (1.00) REF (1.00) 
 
37 REF (1.00) REF (1.00) 
  10-20 3320 145 1.12 (0.85-1.49) 0.95 (0.70-1.27) 
 
149 1.17 (0.88-1.55) 0.94 (0.70-1.26) 
 
70 0.99 (0.66-1.47) 1.06 (0.70-1.62) 
  >20 2348 104 1.18 (0.87-1.60) 0.83 (0.60-1.16) 
 
121 1.40 (1.04-1.88) 0.96 (0.69-1.33) 
 
35 0.70 (0.44-1.12) 0.79 (0.47-1.33) 
Histological grade (Elston) †     
   
  
   
  
  
  Low 899 26 REF (1.00) REF (1.00) 
 
26 REF (1.00) REF (1.00) 
 
22 REF (1.00) REF (1.00) 
  Moderate 2390 111 1.62 (1.06-2.49) 1.52 (0.98-2.34) 
 
120 1.78 (1.16-2.72) 1.65 (1.07-2.54) 
 
44 0.72 (0.43-1.20) 0.77 (0.45-1.29) 
  High 1476 91 1.90 (1.22-2.95) 1.53 (0.95-2.47) 
 
98 2.00 (1.29-3.09) 1.73 (1.08-2.77) 
 
36 0.70 (0.41-1.20) 0.77 (0.42-1.42) 
Lymph nodes     
   
  
   
  
  
   Negative 4702 177 REF (1.00) REF (1.00) 
 
183 REF (1.00) REF (1.00) 
 
87 REF (1.00) REF (1.00) 
   Positive 2750 149 1.43 (1.15-1.78) 1.30 (1.00-1.70) 
 
162 1.51 (1.22-1.86) 1.22 (0.95-1.59) 
 
54 0.97 (0.69-1.37) 1.20 (0.79-1.80) 
ER status     
   
  
   
  
  
  Positive 5952 236 REF (1.00) REF (1.00) 
 
276 REF (1.00) REF (1.00) 
 
111 REF (1.00) REF (1.00) 
  Negative 1271 73 1.36 (1.04-1.77) 1.33 (0.82-2.15) 
 
62 0.95 (0.72-1.26) 0.95 (0.58-1.57) 
 
28 0.96 (0.63-1.46) 0.76 (0.37-1.58) 
Distant Metastasis     
   
  
   
  
  
   Negative 7654 328 REF (1.00) REF (1.00) 
 
342 REF (1.00) REF (1.00) 
 
145 REF (1.00) REF (1.00) 
   Positive 136 4 1.51 (0.56-4.06) -- 
 
11 4.25 (2.33-7.78) -- 
 
1 0.95 (0.13-6.78) -- 
Treatment characteristics 
            
Endocrine therapy 
            
 No 1346 75 REF (1.00) REF (1.00) 
 
64 REF (1.00) REF (1.00) 
 
33 REF (1.00) REF (1.00) 
 Yes 6303 252 0.77 (0.60-1.00) 1.04 (0.65-1.68) 
 
283 1.07 (0.81-1.41) 1.22 (0.75-2.00) 
 
112 0.90 (0.60-1.33) 0.62 (0.31-1.23) 
Chemotherapy †     
   
  
   
  
  
  No 4912 158 REF (1.00) REF (1.00) 
 
159 REF (1.00) REF (1.00) 
 
80 REF (1.00) REF (1.00) 
  Yes 2720 167 1.46 (1.16-1.84) 1.16 (0.86-1.55) 
 
186 1.56 (1.25-1.94) 1.36 (1.02-1.81) 
 
64 0.82 (0.58-1.17) 0.82 (0.51-1.29) 
Radiotherapy     
   
  
   
  
  
  No 1810 72 REF (1.00) REF (1.00) 
 
81 REF (1.00) REF (1.00) 
 
31 REF (1.00) REF (1.00) 
  Yes 5839 254 1.01 (0.77-1.31) 1.11 (0.80-1.53) 
 
267 0.92 (0.72-1.19) 1.02 (0.75-1.38) 
 
114 1.06 (0.71-1.57) 0.91 (0.55-1.50) 
Surgery     
   
  
   
  
  
  Partial mastectomy 4627 181 REF (1.00) REF (1.00) 
 
188 REF (1.00) REF (1.00) 
 
92 REF (1.00) REF (1.00) 
  Total mastectomy 3048 147 1.24 (0.99-1.54) 1.18 (0.89-1.57) 
 
160 1.29 (1.04-1.60) 1.13 (0.86-1.49) 
 
53 0.80 (0.57-1.12) 0.83 (0.53-1.31) 
 
Total no. refers to the total number of patients. No. refers to the number of observed cases. In model A, hazard ratios were estimated with adjustment for age and calendar period only. In model B, 
hazard ratios are adjusted for all variables listed in the table. Missingness on individual variables < 5 %, except for histological grade (39.0%, N = 3,042), which was included in the Stockholm-Gotland 
Breast Cancer Register from 2004 onward and ER status (7.6%, N = 590). Patients with distant metastases at diagnosis are not included in model B (because of missing values on tumor characteristics) 
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eTable 1. International Classification of Diseases (ICD) codes for depression, anxiety and stress-related disorders. 
ICD code Description No. of cases in nationwide cohort 
Depression   
F320 Mild depressive episode 64 
F321 Moderate depressive episode 205 
F322 Severe depressive episode without psychotic symptoms 100 
F323 Severe depressive episode with psychotic symptoms 19 
F328 Other depressive episodes 15 
F329 Depressive episode, unspecified 272 
F330 Recurrent depressive disorder, current episode mild 20 
F331 Recurrent depressive disorder, current episode moderate 52 
F332 Recurrent depressive disorder, current episode severe without psychotic symptoms 18 
F333 Recurrent depressive disorder, current episode severe with psychotic symptoms 4 
F334 Recurrent depressive disorder, currently in remission 19 
F338 Other recurrent depressive disorders 2 
F339 Recurrent depressive disorder, unspecified 25 
Anxiety     
F400 Agoraphobia 13 
F401 Social phobias 16 
F402 Specific (isolated) phobias 7 
F410 Panic disorder (episodic paroxysmal anxiety) 54 
F411 Generalized anxiety disorder 43 
F412 Mixed anxiety and depressive disorder 287 
F413 Other mixed anxiety disorders 3 
F418 Other specified anxiety disorders 2 
F419 Anxiety disorder, unspecified 188 
Stress related disorders  
 
F430 Acute stress reaction 185 
F431 Post-traumatic stress disorder 31 
F432 Adjustment disorders 88 
F438 Other reactions to severe stress 34 
F439 Reaction to severe stress, unspecified 72 
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eTable 2. Standardized incidence ratios for psychiatric medications in the nationwide cohort of invasive and 
in-situ breast cancer patients, overall and stratified by age and time since diagnosis  
 
 Antidepressant  Anxiolytics  Hypnotics and sedatives 
  No. SIR(95%CI) 
 
No. SIR(95%CI)   No. SIR(95%CI) 
Overall         
Invasive 1758 1.95 (1.86-2.04) 
 
2610 2.52 (2.43-2.62) 
 
3578 3.55 (3.43-3.66) 
In-situ 160 1.58 (1.36-1.85)  200 1.64 (1.43-1.88) 
 
252 2.05 (1.81-2.32) 
Age group         
Invasive         
20-44 years 238 2.43 (2.14-2.76)  342 3.96 (3.56-4.40)  479 6.31 (5.77-6.90) 
45-54 years 428 2.23 (2.02-2.45)  588 3.04 (2.81-3.30)  899 4.63 (4.33-4.94) 
55-64 years 501 2.00 (1.83-2.18)  766 2.50 (2.33-2.68)  1104 3.55 (3.35-3.77) 
65-80 years 591 1.64 (1.51-1.77)  914 2.04 (1.91-2.17)  1096 2.56 (2.41-2.72) 
In-situ         
20-44 years 16 1.36 (0.84-2.23)  18 1.52 (0.96-2.42)  23 2.09 (1.39-3.15) 
45-54 years 53 1.93 (1.48-2.53)  51 1.69 (1.28-2.22)  71 2.21 (1.75-2.79) 
55-64 years 45 1.54 (1.15-2.07)  60 1.57 (1.22-2.02)  71 1.84 (1.46-2.32) 
65-80 years 46 1.40 (1.05-1.87)  71 1.69 (1.34-2.14)  87 2.12 (1.72-2.62) 
Time since diagnosis         
Invasive         
      0-0.5 427 2.14 (1.95-2.36)  1349 6.13 (5.81-6.47) 
 
2133 9.19 (8.81-9.59) 
      0.5-1 472 2.62 (2.40-2.87)  384 1.90 (1.72-2.10) 
 
525 2.62 (2.41-2.85) 
      1-2 527 1.92 (1.76-2.09)  470 1.47 (1.35-1.61) 
 
541 1.77 (1.63-1.93) 
      2-4.5 332 1.34 (1.20-1.49)  407 1.38 (1.26-1.52) 
 
379 1.40 (1.27-1.55) 
In-situ       
 
  
      0-0.5 46 2.09 (1.57-2.79)  97 3.86 (3.17-4.71) 
 
131 4.93 (4.15-5.85) 
      0.5-1 30 1.49 (1.04-2.13)  22 0.93 (0.61-1.41) 
 
37 1.53 (1.11-2.11) 
      1-2 53 1.70 (1.30-2.22)  49 1.28 (0.97-1.70) 
 
48 1.26 (0.95-1.68) 
      2-4.5 31 1.12 (0.79-1.59)   32 0.91 (0.64-1.28)   36 1.06 (0.76-1.47) 
 
* Abbreviations: SIR = standardized incidence ratio; No. refers to the number of observed cases; CI = confidence interval. SIRs 
for first use of antidepressant (ATC code: N06A), anxiolytics (ATC: N05B), hypnotics and sedatives (ATC: N05C) in the 
nationwide breast cancer cohort compared to the general female population (age 20-80 years). SIRs are standardized by calendar 




eTable 3. Hazard ratios of depression, anxiety and stress-related disorders in the regional cohort of invasive 
breast cancer patients - grouped models. 
  Depression  Anxiety  Stress-related disorders 
 Total No. No. 
Grouped model 
HR (95%CI) 
 No. Grouped model HR (95%CI) 
 No. Grouped model HR (95%CI) 
Patients characteristics          
Age at diagnosis          
  23-44 years 1012 86 REF (1.00)  114 REF (1.00)  47 REF (1.00) 
  45-54 years 1913 115 0.69 (0.52-0.91)  109 0.49 (0.38-0.64)  64 0.70 (0.48-1.02) 
  55-64 years 2629 80 0.34 (0.25-0.47)  86 0.27 (0.21-0.36)  26 0.20 (0.13-0.33) 
  65-80 years 2386 54 0.27 (0.19-0.38)  53 0.19 (0.13-0.26)  10 0.09 (0.05-0.18) 
Comorbidities†          
  No 6797 287 REF (1.00) 
 
304 REF (1.00) 
 
128 REF (1.00) 
  Yes  1143 48 1.38 (1.01-1.89) 
 
58 1.66 (1.25-2.22) 
 
19 1.48 (0.91-2.41) 














  <10 1867 71 REF (1.00)  69 REF (1.00)  37 REF (1.00) 
  10-20 3320 145 0.99 (0.74-1.32)  149 1.05 (0.78-1.41)  70 1.03 (0.68-1.56) 
  >20 2348 104 0.92 (0.67-1.27)  121 1.14 (0.83-1.57)  35 0.74 (0.45-1.21) 
Histological grade (Elston) †              
  Low 899 26 REF (1.00)  26 REF (1.00)  22 REF (1.00) 
  Moderate 2390 111 1.53 (0.99-2.36)  120 1.64 (1.07-2.52)  44 0.74 (0.44-1.25) 
  High 1476 91 1.62 (1.02-2.58)  98 1.89 (1.20-2.99)  36 0.73 (0.41-1.31) 
Lymph nodes              
   Negative 4702 177 REF (1.00)  183 REF (1.00)  87 REF (1.00) 
   Positive 2750 149 1.42 (1.13-1.79)  162 1.40 (1.12-1.75)  54 1.07 (0.75-1.52) 
ER status              
  Positive 5952 236 REF (1.00)  276 REF (1.00)  111 REF (1.00) 















 No 1346 75 REF (1.00)  64 REF (1.00)  33 REF (1.00) 
 Yes 6303 252 0.87 (0.66-1.14)  283 1.27 (0.96-1.69)  112 0.83 (0.55-1.26) 
Chemotherapy†              
  No 4912 158 REF (1.00)  159 REF (1.00)  80 REF (1.00) 
  Yes 2720 167 1.36 (1.07-1.73)  186 1.59 (1.26-2.01)  64 0.81 (0.56-1.18) 
Radiotherapy              
  No 1810 72 REF (1.00)  81 REF (1.00)  31 REF (1.00) 
  Yes 5839 254 1.20 (0.88-1.63)  267 1.09 (0.81-1.46)  114 0.89 (0.55-1.44) 
Surgery              
  Partial mastectomy 4627 181 REF (1.00)  188 REF (1.00)  92 REF (1.00) 
  Total mastectomy 3048 147 1.28 (0.98-1.66)  160 1.27 (0.98-1.64)  53 0.77 (0.51-1.17) 
 
Abbreviations: HR = hazard ratio; CI = confidence interval. Hazard ratios were estimated from flexible parametric survival models with time since diagnosis as 
underlying time scale. Grouped models include respectively all patient, tumor or treatment characteristics with additional adjustment for age and calendar period.  
Missingness on individual variables < 5 %, except for histological grade (39.0%, N = 3,042), which was included in the Stockholm-Gotland Breast Cancer 
Register from 2004 onward and ER status (7.6%, N = 590). Patients with distant metastases at diagnosis are not included in this model (because of missing values 
on tumor characteristics) as these patients do not undergo routine surgery. † The proportional hazards assumption was met for all variables, except for 





eTable 4. Time-dependent effects of comorbidity, histological grade and chemotherapy in the regional cohort of invasive breast cancer patients, with hazard ratios at 
specific time points following diagnosis. 
 HR of depression (95% CI)  HR of anxiety (95% CI) 
 Year 1 Year 2 Year 5 Year 10  Year 1 Year 2 Year 5 Year 10 
Patient characteristics          
Comorbidity          
  No REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) 
  Yes 1.01 (0.59-1.73) 1.38 (0.82-2.33) 1.80 (1.22-2.65) 2.09 (0.93-4.67)  0.93 (0.54-1.61) 1.47 (0.92-2.35) 2.56 (1.74-3.76) 2.46 (1.36-4.46) 
Tumor characteristics          
Histological grade 
(Elston)          
  Low REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) 
  Moderate 2.69 (1.31-5.51) 1.86 (0.93-3.71) 0.80 (0.43-1.49) 0.34 (0.08-1.43)  2.41 (1.12-5.21) 2.67 (1.14-6.25) 1.09 (0.56-2.11) 0.75 (0.26-2.17) 
  High 2.77 (1.29-5.94) 1.62 (0.76-3.43) 1.06 (0.57-1.97) 0.95 (0.25-3.62)  2.55 (1.16-5.60) 3.01 (1.27-7.17) 0.90 (0.42-1.93) 0.55 (0.17-1.76) 
Treatment characteristics          
Chemotherapy   
   
   
   
  No REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) REF (1.00) 
  Yes 1.45 (0.96-2.19) 0.99 (0.65-1.52) 0.99 (0.70-1.39) 1.03 (0.56-1.92)  2.28 (1.48-3.50) 1.82 (1.21-2.72) 0.85 (0.57-1.27) 0.80 (0.50-1.28) 
Abbreviations: HR = hazard ratio; CI = confidence interval. Time-dependent hazard ratios as estimated from flexible parametric survival models with time since diagnosis as underlying time scale, allowing the effect of each characteristic to vary 




eTable 5. Hazard ratios of depression, anxiety and stress-related disorders by patient, tumor and treatment characteristics in the regional cohort of 




HR (95%CI) of depression  
 
HR (95%CI) of anxiety 
 
HR( 95%CI) of stress-related disorder 
 Censoring at recurrence 










Patients characteristics           
Age at diagnosis           
23-44 years  REF (1.00) REF (1.00)   REF (1.00) REF (1.00)  REF (1.00) REF (1.00) 
45-54 years  0.79 (0.58-1.07) 0.82 (0.60-1.12)   0.61 (0.45-0.81) 0.61 (0.45-0.81)  0.77 (0.51-1.19) 0.79 (0.50-1.26) 
55-64 years  0.44 (0.32-0.61) 0.43 (0.30-0.60)   0.34 (0.25-0.47) 0.32 (0.23-0.45)  0.23 (0.14-0.40) 0.21 (0.12-0.40) 
65-80 years  0.37 (0.25-0.54) 0.32 (0.21-0.50)   0.28 (0.19-0.41) 0.16 (0.10-0.27)  0.11 (0.05-0.23) 0.13 (0.06-0.30) 
Tumor characteristics             
Size in mm           
  <10  REF (1.00) REF (1.00)   REF (1.00) REF (1.00)  REF (1.00) REF (1.00) 
  10-20  0.93 (0.69-1.26) 0.88 (0.64-1.22)   0.89 (0.65-1.22) 0.74 (0.53-1.05)  1.04 (0.66-1.63) 1.05 (0.63-1.76) 
  >20  0.82 (0.58-1.15) 0.69 (0.48-1.01)   0.90 (0.63-1.27) 0.94 (0.65-1.35)  0.81 (0.47-1.41) 0.85 (0.46-1.59) 
Histological grade (Elston)            
  Low  REF (1.00) REF (1.00)   REF (1.00) REF (1.00)  REF (1.00) REF (1.00) 
  Moderate  1.51 (0.97-2.33) 1.42 (0.88-2.29)   1.56 (1.00-2.43) 2.07 (1.19-3.60)  0.79 (0.46-1.36) 0.86 (0.46-1.60) 
  High  1.50 (0.92-2.43) 1.46 (0.86-2.46)   1.60 (0.98-2.61) 2.18 (1.20-3.95)  0.69 (0.36-1.33) 0.78 (0.37-1.65) 
Lymph nodes           
   Negative  REF (1.00) REF (1.00)   REF (1.00) REF (1.00)  REF (1.00) REF (1.00) 
   Positive  1.30 (0.98-1.71) 1.25 (0.93-1.69)   1.09 (0.82-1.44) 1.40 (1.04-1.90)  1.05 (0.68-1.64) 1.14 (0.69-1.87) 
ER status           
  Positive  REF (1.00) REF (1.00)   REF (1.00) REF (1.00)  REF (1.00) REF (1.00) 
  Negative  1.40 (0.84-2.33) 0.95 (0.55-1.66)   0.75 (0.43-1.29) 0.75 (0.42-1.36)  0.89 (0.41-1.95) 0.62 (0.25-1.51) 
Treatment characteristics           
Endocrine therapy           
 No  REF (1.00) REF (1.00)   REF (1.00) REF (1.00)  REF (1.00) REF (1.00) 
 Yes  1.11 (0.67-1.84) 0.77 (0.45-1.31)   1.02 (0.60-1.73) 1.01 (0.57-1.77)  0.68 (0.33-1.44) 0.51 (0.22-1.16) 
Chemotherapy            
  No  REF (1.00) REF (1.00)   REF (1.00) REF (1.00)  REF (1.00) REF (1.00) 
  Yes  1.19 (0.87-1.61) 1.28 (0.92-1.79)   1.62 (1.19-2.21) 1.40 (1.01-1.96)  0.93 (0.56-1.53) 0.94 (0.53-1.65) 
Radiotherapy           
  No  REF (1.00) REF (1.00)   REF (1.00) REF (1.00)  REF (1.00) REF (1.00) 
  Yes  1.12 (0.80-1.57) 0.99 (0.69-1.43)   0.96 (0.69-1.33) 0.96 (0.67-1.37)  0.93 (0.54-1.59) 0.66 (0.36-1.22) 
Surgery           
  Partial mastectomy  REF (1.00) REF (1.00)   REF (1.00) REF (1.00)  REF (1.00) REF (1.00) 
  Total mastectomy  1.15 (0.85-1.55) 1.09 (0.79-1.51)   1.13 (0.83-1.52) 1.01 (0.74-1.38)  0.84 (0.52-1.37) 0.58 (0.33-1.03) 
 
*All hazard ratios are multivariable adjusted and refer to analyses with either additional censoring at current events or new-onset comorbidity. Missingness on individual variables < 5%, except for 
histological grade (39.0%, N = 3,042), which was included in the Stockholm-Gotland Breast Cancer Register from 2004 onward and ER status (7.6%, N = 590). ). Patients with distant metastases at 
diagnosis are not analyzed in the models (because of missing values on tumor characteristics) as these patients do not undergo routine surgery. 
 
 
 
